# Ramez N. Eskander

Source: https://onco.cc/people/ramez-eskander/  
OnCo record `ramez-eskander` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease.

## Summary

Ramez Eskander was principal investigator of NRG-GY018 (KEYNOTE-868), which showed adding pembrolizumab to carboplatin-paclitaxel improves progression-free survival in advanced or recurrent endometrial cancer in both mismatch repair-deficient and proficient populations, published alongside RUBY to establish chemo-immunotherapy as first-line standard. He leads gynaecologic oncology trials at UC San Diego and within NRG Oncology.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: endometrial; immunotherapy; nrg-oncology
- Role: Professor of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego Moores Cancer Center
- Specialisms: Endometrial cancer; Immunotherapy; Gynaecologic oncology surgery; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Eskander%20RN%5BAuthor%5D%20endometrial%20pembrolizumab

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [GOG Foundation](https://onco.cc/companies/gog-foundation/)
- institutions: [UC San Diego Moores Cancer Center](https://onco.cc/institutions/ucsd-moores/)
- trials: [NRG-GY018 / KEYNOTE-868](https://onco.cc/trials/nrg-gy018-keynote-868/)

---
JSON: https://onco.cc/api/v1/entities/ramez-eskander.json